港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

湖南麥濟生物技術股份有限公司（臨時代碼）

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

新股消息 | 麥濟生物港股IPO招股書失效

科學家創業9年，燒錢8億元！對賭上市倒計時僅剩1年，深陷專利糾紛的麥濟生物如何撐起26億元估值？

每日经济新闻

三生國健專利狙擊麥濟生物，估值26億的IPO之路暗藏三重風險

三生國健與麥濟生物專利戰再開打

麥濟生物港股IPO收證監會反饋意見：需説明股權變動合規性、專利糾紛影響等問題

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91209/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91209","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","market":"HK","secType":"STK","nameCN":"湖南麥濟生物技術股份有限公司（臨時代碼）","latestPrice":0,"timestamp":1774425600000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":0,"latestTime":"03-25 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91209\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91209\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91209\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91209\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603668855","title":"新股消息 | 麥濟生物港股IPO招股書失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668855","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668855?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 10:27","pubTimestamp":1768357655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，湖南麦济生物技术股份有限公司-B(简称：麦济生物)于2025年7月14日所递交的港股招股书满6个月，于2026年1月14日失效，递表时中金为其独家保荐人。招股书显示，麦济生物是一家处于注册临床阶段的生物制药公司，专注于发现、开发及商业化创新生物制剂，以解决有关过敏性及自身免疫疾病以及其他炎症与免疫性疾病方面尚未满足的医疗需求。自2016年成立以来，公司已自主研发并建立一条由八款创新候选产品组成的强大管线，包括核心产品MG-K10、关键产品MG-014及MG-013，以及五款其他候选产品。所有该等产品均为通过公司自有技术平台发现及开发的新一代长效抗体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91209"],"gpt_icon":0},{"id":"2593457143","title":"科學家創業9年，燒錢8億元！對賭上市倒計時僅剩1年，深陷專利糾紛的麥濟生物如何撐起26億元估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593457143","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593457143?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:51","pubTimestamp":1766454660,"startTime":"0","endTime":"0","summary":"临近年末，对递表港交所近半年却仍未进入聆讯的IPO公司而言，上市冲刺失败几率正在放大。公司今年7月14日向港交所提交上市申请书，截至目前尚未进入聆讯。自2016年成立以来，麦济生物已自主研发并建立一条由八款创新候选产品组成的管线。就在上个月，三生国健又提交了针对麦济生物一项核心专利无效宣告请求，是否会对MG-K10上市进程造成影响尚未可知。与此同时，麦济生物净亏损分别高达2.53亿元、","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161022","91209"],"gpt_icon":0},{"id":"2583490526","title":"三生國健專利狙擊麥濟生物，估值26億的IPO之路暗藏三重風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2583490526","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583490526?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 13:34","pubTimestamp":1763098440,"startTime":"0","endTime":"0","summary":"三生国健与麦济生物围绕IL-4R抗体专利的争夺战再度升级。11月3日，三生国健公开表示，已向国家知识产权局申请宣告麦济生物核心专利无效，直指其当家产品MG-K10的命脉。这场纠纷背后，不仅是两家药企的技术归属之争，更暴露了麦济生物在冲刺港交所之际面临的专利、财务与市场竞争三重压力。三生国健随后提起诉讼，指控其为“职务发明”。　　麦济生物的财务状况同样令人担忧。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-14/doc-infxiwfa4569789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688336","91209"],"gpt_icon":0},{"id":"2580209904","title":"三生國健與麥濟生物專利戰再開打","url":"https://stock-news.laohu8.com/highlight/detail?id=2580209904","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580209904?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 14:34","pubTimestamp":1762238040,"startTime":"0","endTime":"0","summary":"　　三生国健与麦济生物的专利战有了新进展。　　三生国健表示，2020年，麦济生物的另一项IL-4R专利被上海知识产权法院判决侵权。当时，三生国健起诉麦济生物侵犯其专利权，称涉案专利技术实为职务发明，应归公司所有。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-04/doc-infwfiev0519233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688336","BK0239","91209"],"gpt_icon":0},{"id":"2571638353","title":"麥濟生物港股IPO收證監會反饋意見：需説明股權變動合規性、專利糾紛影響等問題","url":"https://stock-news.laohu8.com/highlight/detail?id=2571638353","media":"新浪证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571638353?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 16:40","pubTimestamp":1759135200,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　麦济生物IPO：8年烧8亿商业化进程仍无时间表 核心产品市场竞争激烈且专利曾陷权属纠纷。　　近日，麦济生物收到证监会关于本次境外上市的备案反馈意见，具体反馈如下，请你公司就以下事项补充说明，请律师核查并出具明确的法律意见：。　　一、关于股权变动。　　五、关于本次发行上市及“全流通”。　　7月14日，麦济生物向港交所递交主板上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-09-29/doc-infsecqp1764022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["YANG","07226","BK4614","91209","HSCEI","HSTECH"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}